First‐trimester exposure to tofacitinib in ulcerative colitis: A case report of a healthy newborn and literature review
Arteen Arzivian, Eva Zhang, Robyn Laube, Rupert W. Leong
Abstract
Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.
Topics & Concepts
TofacitinibMedicineUlcerative colitisVedolizumabPregnancyFirst trimesterObstetricsPediatricsInternal medicineDiseaseFetusRheumatoid arthritisGeneticsBiologyPregnancy and Medication ImpactReproductive System and PregnancyInflammatory Bowel Disease